Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2025 | $14.00 | Outperform | Raymond James |
| 4/29/2025 | $10.00 | Overweight | Cantor Fitzgerald |
| 4/8/2025 | $18.00 | Outperform | Wedbush |
| 2/25/2025 | $26.00 | Buy | Jefferies |
| 10/16/2024 | $22.00 | Outperform → Strong Buy | Raymond James |
| 9/27/2024 | $10.00 → $13.00 | Overweight | JP Morgan |
| 9/19/2024 | $11.00 | Buy | B. Riley Securities |
| 9/9/2024 | $10.00 | Overweight | JP Morgan |
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 2025 Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 4:55 p.m. ET. A live webcast of this presentation can be accessed by visiting "Investor Events" on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentat
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Christopher Wright, MD, PhD, as Chief Medical Officer. Dr. Wright will join Wave's executive team and lead global development, including medical, clinical and regulatory functions, to bring the company's RNA medicines to countless individuals who urgently need them. "Dr. Wright joins us with extensive global development leadership experience spanning both early and late-stage clinical development, including an impressive track-record of success
Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon 53 amenable DMD including statistically significant and clinically meaningful improvement i
Raymond James resumed coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $14.00
Cantor Fitzgerald initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $10.00
Wedbush initiated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $18.00
144 - Wave Life Sciences Ltd. (0001631574) (Subject)
SCHEDULE 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
10-Q - Wave Life Sciences Ltd. (0001631574) (Filer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4/A - Wave Life Sciences Ltd. (0001631574) (Issuer)